2022
DOI: 10.1016/j.apsb.2021.06.014
|View full text |Cite
|
Sign up to set email alerts
|

Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
21
0
2

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 43 publications
(23 citation statements)
references
References 383 publications
(470 reference statements)
0
21
0
2
Order By: Relevance
“…Related to synaptic pathway function, acute TG injection in rats impairs learning and memory ( Taylor et al, 2014 ), in rat hippocampal slices induces long-term depression ( Taylor et al, 2014 ), in rodent hippocampal slices attenuated epileptiform activity at CA3-CA1 synapses as well as spontaneous CA3 pyramidal cell activity ( Stewart et al, 2017 ), and in rodent hippocampal slices decreased GABA A R currents and intrinsic excitability ( Stewart et al, 2020 ). O-GlcNAcylation has been shown to regulate cellular clock oscillation, the level and stability of clock regulators ( Li et al, 2013 ), as perturbation of the sleep/wake cycle occurs in neurodegenerative disease patients, O-GlcNAcylation of circadian regulators may be important for disease pathogenesis and/or therapeutic considerations ( Austad et al, 2021 ).…”
Section: Resultsmentioning
confidence: 99%
“…Related to synaptic pathway function, acute TG injection in rats impairs learning and memory ( Taylor et al, 2014 ), in rat hippocampal slices induces long-term depression ( Taylor et al, 2014 ), in rodent hippocampal slices attenuated epileptiform activity at CA3-CA1 synapses as well as spontaneous CA3 pyramidal cell activity ( Stewart et al, 2017 ), and in rodent hippocampal slices decreased GABA A R currents and intrinsic excitability ( Stewart et al, 2020 ). O-GlcNAcylation has been shown to regulate cellular clock oscillation, the level and stability of clock regulators ( Li et al, 2013 ), as perturbation of the sleep/wake cycle occurs in neurodegenerative disease patients, O-GlcNAcylation of circadian regulators may be important for disease pathogenesis and/or therapeutic considerations ( Austad et al, 2021 ).…”
Section: Resultsmentioning
confidence: 99%
“…Metabolic decline occurs in the brain during normal aging and can be further enhanced by the development and progression of neurodegenerative diseases. Mitochondrial dysfunction, which is associated with increased oxidative stress, is a major driving force of the progression of Alzheimer’s, Parkinson’s, and Huntington’s disease, as well as several other neurological disorders ( Lin and Beal, 2006 ; Austad et al, 2021 ). The progressive loss of glucose metabolism is also a prevalent feature of neurodegenerative disease, as indirectly shown by FDG-PET and MRI imaging, as well as measurement of concentrations of lactate, pyruvate, and TCA cycle metabolites in patient cerebrospinal fluid ( Parnetti et al, 1995 ; Redjems-Bennani et al, 1998 ; Buckner et al, 2005 ; Edison et al, 2007 ; Schroeter et al, 2009 ; La Joie et al, 2012 ; Liguori et al, 2016 ; Marchitelli et al, 2018 ; Chen et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…Oxidative stress is a prevalent feature of stroke and neurodegenerative diseases ( Malkus et al, 2009 ; Redmann et al, 2018 ; Hill et al, 2019 ; Austad et al, 2021 ). As a major consequence of oxidative stress, accumulation of lipid peroxidation products and their adduction to target molecules is prevalent in the progression of these pathologies ( Butterfield and Lauderback, 2002 ; Muralikrishna Adibhatla and Hatcher, 2006 ; Sultana et al, 2006 ; Ferretti et al, 2008 ; Butterfield et al, 2010 ).…”
Section: Introductionmentioning
confidence: 99%
“…Overall, current preventive and/or therapeutic strategies for targeting mitochondrial dysfunction primarily focus on antioxidants, anti-apoptotic agents and agents that improve glucose metabolism and mitochondrial bioenergetics [136][137][138]. Many of these approaches have shown clear cognitive benefits in preclinical investigations in AD models [138][139][140]. However, in the clinical practice, most interventions have not been adequate in preventing, delaying or even reversing the cognitive decline [141,142].…”
Section: Therapeutic Strategies Targeting Mitochondria For the Treatm...mentioning
confidence: 99%